34 studies found for:    " December 08, 2010":" January 07, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Download search resultsDownload the search results for:
" December 08, 2010":" January 07, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION] (34 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Active, not recruiting A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
2 Completed
Has Results
Two Approaches to Routine HIV Testing in a Hospital Emergency Department
Condition: HIV Infections
Interventions: Procedure: Oral HIV screening;   Procedure: Fingerstick HIV screening
3 Completed Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
Condition: HIV Infection
Intervention: Biological: Fluzone®
4 Unknown  Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection
Conditions: HIV Infections;   Liver Toxicity;   Hepatitis Co-infection
Intervention:
5 Completed The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1
Condition: HIV Infection
Intervention: Drug: Efavirenz
6 Completed Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines
Condition: HIV Infections
Interventions: Biological: Adjuvanted GSK investigational HIV vaccine formulation 1;   Biological: Adjuvanted GSK investigational HIV vaccine formulation 2;   Biological: Ad35 investigational HIV vaccine;   Biological: Placebo (saline)
7 Completed TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir
Condition: HIV Infections
Interventions: Drug: TMC278;   Drug: Raltegravir
8 Completed The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)
Condition: HIV Infection
Intervention: Drug: Efavirenz
9 Completed Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
Condition: HIV Infection
Interventions: Drug: Aprepitant;   Drug: Aprepitant placebo
10 Completed Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults
Condition: HIV Infections
Interventions: Biological: Profectus HIV MAG pDNA vaccine;   Biological: IL-12;   Other: Placebo
11 Active, not recruiting Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-G DNA Vaccine;   Biological: MVA-CMDR Vaccine;   Biological: Placebo PENNVAX-G Vaccine;   Biological: Placebo MVA-CMDR Vaccine
12 Unknown  Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
Conditions: Children With Confirmed HIV Infection;   Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose;   Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
Intervention: Drug: Mycobutin
13 Completed Effects of Growth Hormone Releasing Hormone in HIV
Conditions: HIV;   HIV Lipodystrophy
Interventions: Drug: tesamorelin;   Drug: placebo
14 Active, not recruiting Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Condition: HIV Dementia
Intervention: Drug: Atorvastatin
15 Active, not recruiting TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Adults Coming From Any of the Three Ongoing Tibotec-Sponsored Studies With DRV
Condition: HIV-1 Infections
Interventions: Drug: Darunavir;   Drug: ritonavir
16 Suspended A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
Condition: Human Immunodeficiency Virus I Infection
Interventions: Drug: GSK1349572;   Drug: GSK2248761
17 Active, not recruiting
Has Results
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: Dolutegravir;   Drug: Atripla;   Drug: Abacavir/Lamivudine;   Drug: Abacavir/Lamivudine Placebo;   Drug: Dolutegravir placebo;   Drug: Atripla placebo
18 Completed Recovery Management Intervention in China
Conditions: Methadone;   HIV Infections
Intervention: Behavioral: Recovery management
19 Completed Pilot Study of Metabolic Syndromes and HIV Infections in Indian Tibetans
Conditions: Metabolic Syndromes;   HIV Infection
Intervention:
20 Unknown  Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.
Condition: HIV Integrase, HIV Protease.
Interventions: Drug: Raltegravir;   Drug: Darunavir

Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results
Indicates status has not been verified in more than two years